Company Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.
The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.
The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Country | Israel |
| Founded | 2017 |
| IPO Date | Dec 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Alon Ben-Noon |
Contact Details
Address: 11 Hamenofim St., Building B Herzliya, L3 4672562 Israel | |
| Phone | 972-9-9531142 |
| Website | neurosense-tx.com |
Stock Details
| Ticker Symbol | NRSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001875091 |
| CUSIP Number | M74240108 |
| ISIN Number | IL0011809592 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Or Eisenberg | Chief Financial Officer |
| Dr. Ferenc Tracik M.D. | Chief Medical Officer |
| Alon Ben-Noon | Co-Founder, Chief Executive Officer and Director |
| Hagit Binder | Chief Operation Officer |
| Dr. Niva Russek-Blum Ph.D. | Chief Technology Officer |
| Yael Barak | Vice President of Quality and Compliance |
| Keren Pushett | Head of Human Resources |
| Eidan Loushi | C.R.A. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 6-K | Report of foreign issuer |
| May 10, 2024 | F-1 | Registration statement for certain foreign private issuers |
| May 7, 2024 | 6-K | Report of foreign issuer |
| Apr 25, 2024 | D | Notice of Exempt Offering of Securities |
| Apr 12, 2024 | 424B5 | Filing |
| Apr 12, 2024 | 6-K | Report of foreign issuer |
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | EFFECT | Notice of Effectiveness |
| Apr 8, 2024 | EFFECT | Notice of Effectiveness |